SpyGlass Pharma (SGP)
Develops sustained drug delivery for chronic eye conditions within established surgical workflows.
$28.35
At close+1.49 (+5.55%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions35 holders · as of Mar 31, 2026 | 75.83% | 25.35M shares | |
| Strategic holders1 holder · as of Feb 10, 2026 | 9.90% | 3.31M shares | |
| Otherremainder | 14.27% | 4.77M shares |
33.43M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
35 holders · 25.35M shares · 35 new positions · 35 increased · 0 reduced · 0 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 8.02M | 23.99% | +8.02Mnew | May 15, 2026 |
| Nea Management Company, LLC | 7.39M | 22.11% | +7.39Mnew | May 15, 2026 |
| Sands Capital Ventures, LLC | 2.50M | 7.48% | +2.50Mnew | May 8, 2026 |
| Samsara Biocapital, LLC | 2.11M | 6.31% | +2.11Mnew | May 15, 2026 |
| Price T Rowe Associates Inc /MD/ | 704.4K | 2.11% | +704.4Knew | May 15, 2026 |
| Vestal Point Capital, LP | 666.8K | 1.99% | +666.8Knew | May 15, 2026 |
| JPMorgan Chase & Co | 577.1K | 1.73% | +577.1Knew | May 13, 2026 |
| Deerfield Management Company, L.P. (Series C) | 550.0K | 1.65% | +550.0Knew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Vensana Capital I GP, LLC | 9.90% | 3.31M | 13D | Feb 10, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.